The Ovarian Cancer drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Ovarian cancer is the third commonest cause of cancer death from gynaecologic tumours in Kenya. Ovarian Cancer largely remains asymptomatic in the early stages and is diagnosed in advanced stages when the prognosis is poor. The poor prognosis is further worsened by the lack of train gynaecologic oncologist. The standard treatment involves surgery followed by chemotherapy. According to GLOBOCAN 2020, number of new cases of ovarian cancer reported were 1,126 which accounted for 4.2% of all the cancer cases among females of all ages in Kenya.
The market is driven by a rise in new cases of ovarian cancer. The need for more effective treatment options is boosting the market.
Improvement in the diagnostic capabilities in the country will propel growth in the ovarian cancer drugs market in Kenya in the forecasted period.
Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consists of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions.
Combination drugs reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, and reduce side effects.
However, low levels of awareness among women, low uptake of screening and lack of skilled and trained gynaecologic oncologists in the country are among the restraining factors for growth of the ovarian cancer drug market. Some common side effects of carboplatin contain nausea, vomiting, numbness and tingling of extremities, ear infection, pain, weakness, allergic reactions, and hair loss.